Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
SOURCES: •
Chris Snyder • , professor of economics at Dartmouth College.
David Fajgenbaum • , co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
Heather Stone • , health science policy analyst at the Food & Drug Administration.
Sarrin Chethik • , senior policy analyst at the Market Shaping Accelerator.
RESOURCES: •
Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir, • by David Fajgenbaum (2019).
Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, • by Michael Kremer and Rachel Glennerster (2016).
Market Shaping Accelerator • .
CURE ID Registry • .
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.